Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch) - Full Text View

Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)

This study has been completed.

Sponsored by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ClinicalTrials.gov Identifier:	NCT00000444

Purpose

This study will attempt to determine the best time to begin a smoking cessation program in individuals who undergo intensive treatment for alcohol dependence. The goal of this trial is to determine whether a smoking cessation program is more effective if it occurs at the same time as or after treatment for alcohol dependence. The study also will attempt to determine the effect of smoking cessation programs on the outcome of treatment for alcohol dependence.

Condition	Intervention	Phase
Alcoholism Smoking	Drug: nicotine replacement patch	Phase IV

MedlinePlus related topics:

Alcoholism Quitting Smoking Smoking

Drug Information available for:

Nicotine polacrilex Nicotine tartrate Ethanol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Efficacy Study

Official Title:	Timing of Smoking Intervention in Alcohol Treatment

Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):

Estimated Enrollment:	500
Study Start Date:	September 1997
Study Completion Date:	January 2004
Primary Completion Date:	January 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	21 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Meets criteria for alcohol use disorder and other drug dependence.
Complete first week of alcohol treatment program.
Current cigarette smoker (more than 5 cigarettes/day, smoking more than 1 year).

Exclusion Criteria:

Lifetime diagnosis of an excluding psychiatric disorder: bipolar disorder, schizophrenia or other psychotic disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, eating disorder, post- traumatic stress disorder, antisocial personality disorder, or borderline personality disorder.
Unable to participate in protocol due to functional deficits or severe depression.
Suicidal or homicidal ideation.
Current use of disulfiram (Antabuse) or naltrexone (Revia).
Current use of pipes, cigars, or smokeless tobacco and unwillingness to stop.
Lives more than 100 miles from alcohol treatment facility.
No telephone.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000444

Locations


United States, Minnesota
	General Internal Medicine, VA Medical Center
	Minneapolis, Minnesota, United States, 55417

Sponsors and Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

More Information

Study ID Numbers:	NIAAAJOS11124
First Received:	November 2, 1999
Last Updated:	January 25, 2008
ClinicalTrials.gov Identifier:	NCT00000444
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Nicotine polacrilex

Smoking

Nicotine

Mental Disorders

Alcoholism

Substance-Related Disorders

Disorders of Environmental Origin

Alcohol-Related Disorders

Ethanol

Additional relevant MeSH terms:

Habits

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Cholinergic Agonists

Autonomic Agents

Nicotinic Agonists

Physiological Effects of Drugs

Ganglionic Stimulants

Peripheral Nervous System Agents

Cholinergic Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008